BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Danicamtiv readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Danicamtiv\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07210723-596@assetmemo.bio
DTSTAMP:20261121T005453Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Danicamtiv: Phase 2/3 readout est. (NCT07210723)
DESCRIPTION:Danicamtiv\, phase 2/3.\nStudy: A Study of the Efficacy and Saf
 ety of Danicamtiv in Participants With Symptomatic Genetic and Familial Di
 lated Cardiomyopathy\nEstimated primary completion: September 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/danicamtiv#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07210723
URL:https://assetmemo.bio/drug/danicamtiv#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771465-596@assetmemo.bio
DTSTAMP:20261121T005453Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Danicamtiv: Phase 3 readout est. (NCT07771465)
DESCRIPTION:Danicamtiv\, phase 3.\nStudy: A Study of the Long-term Safety a
 nd Efficacy of Danicamtiv in Adults With Symptomatic Genetic and Familial 
 Dilated Cardiomyopathy\nEstimated primary completion: November 2032. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/danicamtiv#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07771465
URL:https://assetmemo.bio/drug/danicamtiv#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
